Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

NCT00259987 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma

Interventions

DRUG: Lapatinib (GW572016) oral tablets

Sponsor

GlaxoSmithKline